Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Investing Activities (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Cash from Investing Activities data on record, last reported at -$158.3 million in Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 746.32% year-over-year to -$158.3 million; the TTM value through Sep 2025 reached -$141.4 million, down 230.44%, while the annual FY2024 figure was $40.2 million, 158.1% up from the prior year.
  • Cash from Investing Activities reached -$158.3 million in Q3 2025 per ASMB's latest filing, down from $17.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $33.0 million in Q1 2022 and bottomed at -$158.3 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is -$2.4 million, with a median of $10.0 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: soared 410.88% in 2022, then crashed 746.32% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$8.5 million in 2021, then skyrocketed by 295.21% to $16.6 million in 2022, then tumbled by 641.32% to -$89.7 million in 2023, then soared by 92.53% to -$6.7 million in 2024, then plummeted by 2263.66% to -$158.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$158.3 million in Q3 2025, $17.0 million in Q2 2025, and $6.6 million in Q1 2025.